Clinical Trials Logo

Filter by:
NCT ID: NCT06109220 Recruiting - Knee Osteoarthritis Clinical Trials

Treatment of Knee Osteoarthritis (KOA) by Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) Into Joint Cavity

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to analyze and study the efficacy and safety of autologous adipose-derived vascular matrix components (SVF) in patients with knee osteoarthritis before and after treatment through clinical evaluation, radiation index, and metabolic index comparison between plasma and irrigation solution before and after SVF injection.

NCT ID: NCT06109207 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the safety and feasibility of anti-programmed cell death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant treatment regimen for patients with resectable esophageal squamous cell carcinoma (ESCC) or or head and neck squamous cell carcinoma(HNSCC).

NCT ID: NCT06109064 Recruiting - Clinical trials for Myelodysplastic Syndromes

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.

NCT ID: NCT06108830 Recruiting - Sleep Disturbance Clinical Trials

Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies

NCT ID: NCT06108739 Recruiting - Clinical trials for Hematologic Malignancy

ATG Plus Low-dose PT-Cy for GVHD Prevention

Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

During the past decades, the wider application of easily available haploidentical donor hematopoietic cell transplant (haplo-HCT) has been made possible through the T cell-replete (TCR) regimens including T cell regulation with anti-thymocyte globulin (ATG)/granulocyte colony-stimulating factor (GCSF) and post-transplant cyclophosphamide (PTCy). To achieve decreased non-relapse mortality (NRM) and improved long-term outcomes in haploidentical transplant, the joint use of ATG and PTCy might effectively reduce graft versus host disease (GVHD) and mortality associated with severe forms of GVHD. Recently, investigators established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse.

NCT ID: NCT06108726 Recruiting - NSCLC Clinical Trials

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

Start date: October 18, 2023
Phase: Phase 2
Study type: Interventional

The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy of local injection of envafolimab combined with chemotherapy in the first-line treatment of non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in the local immune microenvironment before and after immunotherapy, in order to find new indicators for immunotherapy evaluation.

NCT ID: NCT06108596 Recruiting - Clinical trials for Locally Advanced Rectal Adenocarcinoma

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Start date: December 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for locally advanced rectal cancer - a single-center, single-arm, open-label clinical trail.

NCT ID: NCT06108492 Recruiting - Clinical trials for High-risk Non-muscle Invasive Bladder Cancer

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with high-risk non-muscle invasive bladder cancer.

NCT ID: NCT06108362 Recruiting - Acute Kidney Injury Clinical Trials

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

Start date: August 18, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

NCT ID: NCT06107673 Recruiting - Breast Cancer Clinical Trials

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)

Start date: September 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a multi-center, randomized, prospective phase II clinical trial aimed at exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant treatment for ER strong positive(ER≥50%),HER2-negative, Ki-67≤20%,T1-3N1M0 postmenopausal breast cancer. The primary objectives are to demonstrate non-inferiority in efficacy compared to chemotherapy and to assess its superior safety profile.